PCN286 - INCREMENTAL COST-EFFECTIVENESS RATIO FOR THE ANTINEOPLASTIC DRUGS APPROVED AND REJECTED FOR THE VITAL AND ESSENTIAL DRUGS LIST IN 2017 IN RUSSIA
Oct 1, 2018, 00:00
10.1016/j.jval.2018.09.368
https://www.valueinhealthjournal.com/article/S1098-3015(18)33668-4/fulltext
Title :
PCN286 - INCREMENTAL COST-EFFECTIVENESS RATIO FOR THE ANTINEOPLASTIC DRUGS APPROVED AND REJECTED FOR THE VITAL AND ESSENTIAL DRUGS LIST IN 2017 IN RUSSIA
Citation :
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(18)33668-4&doi=10.1016/j.jval.2018.09.368
First page :
Section Title :
Open access? :
No
Section Order :
2274